<DOC>
	<DOCNO>NCT01395641</DOCNO>
	<brief_summary>This Phase I/II trial prove efficacy safety AAV2-hAADC treat patient AADC deficiency .</brief_summary>
	<brief_title>A Phase I/II Clinical Trial Treatment Aromatic L-amino Acid Decarboxylase ( AADC ) Deficiency Using AAV2-hAADC</brief_title>
	<detailed_description>Aromatic L-amino acid decarboxylase ( AADC ) enzyme responsible final step synthesis neurotransmitter dopamine serotonin . AADC deficiency rare genetic disorder . Taiwanese carry high prevalence AADC deficiency due founder mutation IVS6+4 A &gt; T , patient usually die age 5-6 year due severe motor dysfunction . Gene therapy adeno-associated virus ( AAV ) serotype 2 ( AAV2 ) drive human AADC ( hAADC ) test animal model Phase I clinical trial Parkinson disease . We do compassionate treatment 8 patient AADC deficiency AAV2-hAADC demonstrate result among treated patient , 4 could stand support , 3 could sit support , virus-associated toxicity . The long follow exceed 4 year . This study prove safety efficacy AAV2-hAADC treatment patient Aromatic L-amino acid decarboxylase ( AADC ) deficiency .</detailed_description>
	<mesh_term>Dopa Decarboxylase</mesh_term>
	<criteria>1 . A definitive diagnosis AADC deficiency , include CSF study show decreased level HVA 5HIAA , elevate Ldopa level , presence least one AADC gene pathologic mutation . 2 . The patient must clinical symptom AADC deficiency , include hypotonia , dystonia , oculogyric crisis . 3 . The patient must older 24 month age skull bone suitable surgery . 4 . The parent study participant must agree comply good faith require baseline followup assessment . 5 . The parent guardian must understand sign child 's informed consent form . Exclusion criteria 1 . Other significant medical neurological condition would create unacceptable operative risk . Each case individually review final decision shall rest Primary Investigator . 2 . Preexisting immunity AAV may limit AAVmediated gene delivery . Patients antiAAV2 antibody titer high 1.0 OD exclude . 3 . The patient take medicine alter effect clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>24 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Aromatic Amino Acid Decarboxylase</keyword>
	<keyword>AADC</keyword>
	<keyword>DDC</keyword>
	<keyword>Gene Therapy</keyword>
	<keyword>AAV2-AADC</keyword>
	<keyword>Viral Vector</keyword>
	<keyword>Gene Transfer</keyword>
	<keyword>Aromatic L-Amino Acid Decarboxylase Deficiency</keyword>
</DOC>